Home

Crossing the Blood-Brain Barrier with Breakthrough Therapeutics

AngioChem is a clinical-stage biotechnology company discovering and developing breakthrough drugs that are uniquely capable of crossing the blood-brain barrier to treat brain diseases. The company’s proprietary platform for Engineered Peptide Compounds (EPiC) offers a completely new, innovative way to develop drugs to cross the blood-brain barrier and positions AngioChem as a leader in this field. Based on the EPiC platform, AngioChem has created a deep and broad product pipeline, including small and large molecules, for the treatment of a wide range of brain diseases and related disorders, including brain cancer, cancer metastases, neurodegenerative and metabolic diseases.

News & Events

4-June-2010 // Invitation to attend a scientific panel "New Target Therapies for Resistant Cancers", June 7, 2010 from 6:15 am to 7:30 am.

4-June-2010 // Angiochem makes two poster presentations at 2010 Annual Meeting of the American Society of Clinical Oncology from June 4-8, 2010.

2-June-2010 // Angiochem appoints David Scheer to its Board Of Directors Read...

 

News archive

© AngioChem inc., 2006-2007. All rights reserved.
Websited by Emedia Communications Inc.DHTML JavaScript Menu By Milonic

Terms of use